{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:53:29Z","timestamp":1783076009817,"version":"3.54.6"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Therapeutic drug monitoring (TDM) is recommended for opioid maintenance therapy with levomethadone. However, TDM has not yet been applied to monitor opioid withdrawal therapy clinically, although tools to improve it are required.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In this observational cohort study, repeated TDM with levomethadone was performed according to a prospective opioid withdrawal study protocol. Objective and subjective opioid withdrawal symptoms were measured using validated rating scales and correlated to levomethadone plasma concentrations. Plasma levels were measured using high-pressure liquid chromatography with column switching and spectroscopic detection of methadone and its major metabolite.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>This study included 31 opioid-dependent patients who participated in standardized opioid withdrawal therapy. The serum levels of levomethadone were found to be highly variable and below the recommended therapeutic reference range of 250 ng\/mL for maintenance therapy. These serum levels were positively correlated with dosage (r = 0.632; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) and inversely correlated with subjective (r = \u22120.29; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.011) and objective (r = \u22120.28; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.014) withdrawal symptoms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The evidence provided sheds light on how to improve levomethadone withdrawal therapy in patients with opioid dependence. It seems likely that higher initial doses at the beginning and lower dose reductions would have been advantageous. TDM can enhance the safety of opioid withdrawal therapies, minimize withdrawal symptoms, and reduce dropout rates.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001116","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T19:01:35Z","timestamp":1693508495000},"page":"772-776","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Levomethadone Therapeutic Drug Monitoring to Aid Opioid Withdrawal Therapy: A Short Communication"],"prefix":"10.1097","volume":"45","author":[{"given":"Philippe","family":"Pfeifer","sequence":"first","affiliation":[{"name":"University Hospital of Psychiatry and Psychotherapy Bern, Bern, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Hildebrand","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy University Medical Center Mainz, Untere, Mainz, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Angelov","sequence":"additional","affiliation":[{"name":"Psychiatrische Gutachtenpraxis, Nieder-Olm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Havemann-Reinecke","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Medicine G\u00f6ttingen, G\u00f6ttingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6ttcher","sequence":"additional","affiliation":[{"name":"MVZ Medizinische Labore Dessau Kassel GmbH, Dessau, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy University Medical Center Mainz, Untere, Mainz, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Prentice","sequence":"additional","affiliation":[{"name":"SCIVIAS St. Valentinus-Krankenhaus, Kiedrich, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle C.","family":"Roll","sequence":"additional","affiliation":[{"name":"Department of Mental Health, Varisano-Klinikum Frankfurt H\u00f6chst, Frankfurt H\u00f6chst, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"290","DOI":"10.15585\/mmwr.mm6911a4","article-title":"Drug and opioid-involved overdose deaths\u2014United States, 2017-2018","volume":"69","author":"Wilson","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1080\/14656566.2016.1244529","article-title":"Update on pharmacotherapy for treatment of opioid use disorder","volume":"17","author":"Ayanga","year":"2016","journal-title":"Expert Opin Pharmacother."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1192\/j.eurpsy.2021.2219","article-title":"Is Europe facing an opioid crisis like the United States? an analysis of opioid use and related adverse effects in 19 European countries between 2010 and 2018","volume":"64","author":"Pierce","year":"2021","journal-title":"Eur Psychiatry"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.drugalcdep.2018.07.019","article-title":"Methadone maintenance treatment among patients exposed to illicit fentanyl in Rhode Island: safety, dose, retention, and relapse at 6 months","volume":"192","author":"Stone","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence","volume":"41","author":"Eap","year":"2002","journal-title":"Clin Pharmacokinet."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/FTD.0b013e31822fbf7c","article-title":"Therapeutic drug monitoring for drugs used in the treatment of substance-related disorders: literature review using a therapeutic drug monitoring appropriateness rating scale","volume":"33","author":"Br\u00fcnen","year":"2011","journal-title":"Ther Drug Monit."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0376-8716(92)90058-K","article-title":"The use of plasma levels to optimize methadone maintenance treatment","volume":"30","author":"Loimer","year":"1992","journal-title":"Drug Alcohol Depend"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"353","DOI":"10.5055\/jom.2021.0668","article-title":"The duration dilemma in opioid agonist therapy","volume":"17","author":"Dhanda","year":"2021","journal-title":"J Opioid Manag."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/ajad.12862","article-title":"Review article: effective management of opioid withdrawal symptoms: a gateway to opioid dependence treatment","volume":"28","author":"Kosten","year":"2019","journal-title":"Am J Addict."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0376-8716(01)00122-3","article-title":"Predictors for completing an inpatient detoxification program among intravenous heroin users, methadone substituted and codeine substituted patients","volume":"64","author":"Backmund","year":"2001","journal-title":"Drug Alcohol Depend"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/00952998709001515","article-title":"Two new rating scales for opiate withdrawal","volume":"13","author":"Handelsman","year":"1987","journal-title":"Am J Drug Alcohol Abuse"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","article-title":"The clinical opiate withdrawal scale (COWS)","volume":"35","author":"Wesson","year":"2003","journal-title":"J Psychoactive Drugs"},{"key":"R15-20250603","first-page":"2","article-title":"Guideline for quality control in forensic-toxicological analyses","volume":"85","author":"Paul","year":"2018","journal-title":"Toxichem Krimtech"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.clpt.2005.08.011","article-title":"Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment","volume":"78","author":"Crettol","year":"2005","journal-title":"Clin Pharmacol Ther."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/10550887.2022.2057140","article-title":"Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrations","volume":"41","author":"Chalabianloo","year":"2023","journal-title":"J Addict Dis."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drugalcdep.2006.12.018","article-title":"Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment","volume":"89","author":"P\u00e9rez de los Cobos","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/BF02245829","article-title":"Subjective and objective symptoms in relation to plasma methadone concentration in methadone patients","volume":"118","author":"Hiltunen","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0376-8716(00)00121-6","article-title":"Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment","volume":"61","author":"Eap","year":"2000","journal-title":"Drug Alcohol Depend"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1521-0391.2009.00009.x","article-title":"Effect of cocaine use on methadone pharmacokinetics in humans","volume":"19","author":"McCance-Katz","year":"2010","journal-title":"Am J Addict."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/ajad.12183","article-title":"No evidence for reduction of opioid-withdrawal symptoms by cannabis smoking during a methadone dose taper","volume":"24","author":"Epstein","year":"2015","journal-title":"Am J Addict."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"e20193256","DOI":"10.1542\/peds.2019-3256","article-title":"Clinically significant drug-drug interaction between methadone and cannabidiol","volume":"145","author":"Madden","year":"2020","journal-title":"Pediatrics"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:13:18Z","timestamp":1748970798000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001116","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"assertion":[{"value":"2023-03-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}